Developer docs
API playgroundTry for free, no card

Search company profiles

Aavigen Gmbh

Full company profile

uuid00smo1g

Namestring
Aavigen Gmbh
Legal namestring
AaviGen GmbH
Websiteurl
aavigen.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

AaviGen GmbH is a preclinical-stage biotechnology company founded in 2019 and headquartered in Heidelberg, Germany, that develops heart-targeted adeno-associated virus (AAV)-based gene therapies for cardiovascular and cardiopulmonary diseases. The company operates the proprietary next-CAP platform, which combines experimental and bioinformatic methodologies to molecularly engineer AAV capsids with organ-specific tropism, iteratively selecting for manufacturability, transduction, and transgene expression in human-relevant model systems. The resulting portfolio of heart-specific vectors is designed to enable precise, low-dose cardiac gene therapy via peripheral intravenous infusion, addressing the central challenge of off-target delivery and dose-dependent toxicity that constrains conventional AAV approaches.

The company's therapeutic pipeline is organized around five molecular target modules in heart failure: plasma membrane calcium channels, sarcoplasmic reticulum calcium release, mitochondrial energy metabolism, the contractile apparatus (cardiac titin), and beta-adrenergic signaling. Its lead candidate, AVG-101, uses the heart-specific AAV technology to target underlying molecular causes of cardiac muscle dysfunction. Manufacturing is outsourced to CDMO partner SK pharmteco under a multi-year preferred-partner agreement, and a 2026 research collaboration with Circio Holding ASA combines Circio's circVec circular RNA platform with AaviGen's capsids to pursue next-generation low-dose cardiac gene therapy.

AaviGen's business model is consistent with an early-stage biotech: revenue is expected to derive from out-licensing, co-development partnerships, and milestone payments once products advance, with no commercial products or disclosed pricing in market. The company is private, employs 1-10 people, has not publicly disclosed any institutional funding rounds, and is led by a founding team (Prof. Patrick Most, CEO; Dr. Martin Busch, COO; Prof. Marc Lerchenmüller, CFO; Prof. Hugo Katus, CMO) whose prior work includes the Troponin T test and the founding of InoCard (subsequently acquired by uniQure N.V.). It addresses an unmet need of 64.3 million heart failure patients globally with 67-75% five-year mortality, targeting pharmaceutical partners, CDMOs, and academic medical centers through executive-led business development rather than a commercial sales motion.

Short descriptiontext

AaviGen GmbH is a Heidelberg-based preclinical-stage biotech developing heart-targeted AAV gene therapies for cardiovascular disease, using its proprietary next-CAP capsid engineering platform and lead product AVG-101 to address heart failure with organ-specific, low-dose cardiac gene delivery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHeidelberg, Germany
HQ citystring
Heidelberg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac gene therapy, AAV vector engineering, cardiovascular biotechnology, heart failure therapeutics, viral vector platform
Industry3 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiovascular Gene Therapy / Biotechnology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Development and Commercialization
TypeOne Time License
Description

As a preclinical-stage biotech company, AaviGen is in the early phases of developing its gene therapy pipeline for heart failure and cardiovascular diseases. Revenue will derive from licensing deals, co-development partnerships, and eventual product commercialization once therapies receive regulatory approval.

aavigen.com
2Strategic Partnerships and Manufacturing Agreements
TypeProfessional Services
Description

Revenue may be generated through milestone payments and development fees from strategic partnerships such as the SK pharmteco manufacturing agreement and the Circio research collaboration.

aavigen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AaviGen GmbH is a preclinical-stage biotechnology company that develops heart-targeted adeno-associated viral (AAV) vector-based gene therapies for cardiovascular and cardiopulmonary diseases. Its proprietary next-CAP platform engineers heart-specific AAV capsids used to build a cardiac gene therapy pipeline led by AVG-101 for heart failure, addressing five molecular target modules including calcium signaling, mitochondrial energetics, and contractile apparatus function.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AaviGen is a preclinical-stage biotechnology company developing a portfolio of gene therapies for cardiovascular diseases. The company operates its next-CAP Platform to engineer proprietary heart-specific Adeno-Associated Viral (AAV) vectors, which form the foundation of its cardiac gene therapy pipeline. The lead product candidate is AVG-101 for heart failure treatment. The pipeline addresses five therapeutic target areas: plasma membrane calcium channels, sarcoplasmic reticulum calcium cycling, mitochondrial energy metabolism, contractile apparatus (cardiac titin), and beta-adrenergic signaling. The company leverages partnerships for manufacturing (SK pharmteco) and research collaborations (Circio) to advance its vector technology.

Product and service4 records
1next-CAP Platform
CategoryPlatform / Technology
Description

Proprietary hybrid platform that integrates cutting-edge experimental and bioinformatic technologies to molecularly engineer AAV capsids, creating vector libraries with high quantitative and qualitative diversity for organ-specific gene therapy delivery. Intrinsically selects for manufacturability, transduction, and transgene expression through iterative systemic selection in human-relevant model systems.

2AVG-101
CategoryGene Therapy Product Candidate
Description

Lead gene therapy product for the treatment of heart failure, leveraging AaviGen's proprietary heart-specific AAV vector technology to target and reverse underlying molecular causes of heart muscle dysfunction, administered via peripheral intravenous infusion.

3Heart-Specific AAV Vectors
CategoryGene Therapy Delivery Technology
Description

Proprietary organ-specific adeno-associated viral vectors engineered for precise cardiac tropism, enabling targeted delivery of therapeutic genes to cardiomyocytes with unprecedented safety profiles by minimizing off-target organ delivery.

4Cardiac Gene Therapy Pipeline (Five Therapeutic Modules)
CategoryTherapeutic Pipeline
Description

Therapeutic target pipeline addressing five key cardiac molecular areas: (1) plasma membrane voltage-dependent calcium channels, (2) sarcoplasmic reticulum ryanodine receptor calcium release, (3) mitochondria and energy metabolism via F1/0-ATPase, (4) contractile apparatus including cardiac titin and myofilament calcium sensitivity, and (5) beta-adrenergic signaling for desensitized downstream signaling.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

Circio and AaviGen announced a three-stage research collaboration to develop next-generation AAV gene therapy vectors specifically engineered for targeted, low-dose heart gene therapy. The partnership combines Circio's circVec circular RNA platform (demonstrating 40-fold enhanced gene expression in heart tissue) with AaviGen's proprietary heart-targeted AAV capsids. Stages include: (1) production of novel AAVs combining both technologies, (2) in vitro testing and characterization, and (3) in vivo validation focusing on biodistribution and gene expression profiles.

Strategic tierMinorTypeOthersAnnounced on2025-06-04
Description

Will Adams served as Lead Mentor for AaviGen during the German Accelerator U.S. Market Access Life Sciences Program and subsequently joined the AaviGen Advisory Board. He brings U.S. market expertise and industry connections as the company expands globally.

3Prof. Dr. Toni Cathomen
Strategic tierMinorTypeOthersAnnounced on2024-10-09
Description

Prof. Dr. Toni Cathomen joined AaviGen's Scientific Advisory Board as an expert in targeted gene editing. He is Professor of Cell and Gene Therapy and Director of the Institute for Transfusion Medicine and Gene Therapy at the University Medical Center, University of Freiburg. His expertise in designer nucleases (CRISPR-Cas) and gene therapy applications complements AaviGen's AAV vector platform.

aavigen.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-02
Description

SK pharmteco, a global contract development and manufacturing organization (CDMO) for small molecules and advanced therapies, entered a multi-year manufacturing agreement as the preferred manufacturing partner for AaviGen's lead gene therapy product AVG-101 for heart failure. SK pharmteco provides process development and manufacturing of adeno-associated viral-based gene therapies, with recent investments in expanding manufacturing capacity to support development through commercialization.

Strategic tierMinorTypeOthers
Description

Multiple founding team members (Prof. Patrick Most heads the Molecular and Translational Cardiology Division; Prof. Hugo Katus is Director of Cardiology) maintain academic affiliations with the University of Heidelberg. The company was founded on research and translational expertise developed within this academic institution.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

uniQure is an established gene therapy company where AaviGen's CEO previously led cardiac gene therapy development after acquiring InoCard. It is a relevant incumbent comparable given overlapping AAV platform and cardiovascular franchise, but operates at a much larger scale across multiple indications.

TypeDirect peer
Description

Lexeo is a clinical-stage gene therapy company focused on cardiovascular diseases, including AAV-based therapies for cardiomyopathies and heart failure. It is the most direct competitor to AaviGen given overlapping cardiac indication focus and AAV delivery approach.

TypeEmerging player
Description

Solid Biosciences develops AAV gene therapies for cardiac and neuromuscular diseases, including programs for Duchenne muscular dystrophy with cardiac involvement. It overlaps with AaviGen on AAV modality and cardiac targeting, though it is at a later clinical stage.

TypeBroad incumbent
Description

REGENXBIO is a leading AAV gene delivery platform company with NAV technology used across many partners including cardiac programs. It is comparable as a platform-level AAV peer even though its primary commercial focus is ophthalmology and rare disease.

TypeDirect peer
Description

Tenaya is developing genetic medicines for heart disease, including AAV-based gene therapies for cardiomyopathies and heart failure. Its pipeline targeting cardiac genetic and acquired disease states directly overlaps with AaviGen's therapeutic focus.

TypeDirect peer
Description

DiNAQOR is a preclinical-to-clinical-stage platform company developing AAV gene therapies specifically for cardiac diseases. It is highly comparable to AaviGen given the shared heart-targeted AAV modality and pipeline ambition.

TypeEmerging player
Description

Kriya is a gene therapy company developing AAV-based therapies across multiple therapeutic areas with a platform-engineering approach. It is a comparable AAV platform peer, though its current disclosed pipeline does not focus primarily on cardiac indications.

TypeBroad incumbent
Description

Renovacor developed AAV-based gene therapies for cardiomyopathy associated with BAG3 mutations and was acquired by Rocket Pharmaceuticals. Rocket itself is a broader gene therapy company with cardiac-relevant programs, making it a relevant comparable for the cardiac AAV niche AaviGen targets.

TypeBroad incumbent
Description

AskBio, a Bayer subsidiary, develops AAV-based gene therapies across multiple therapeutic areas including cardiac indications (e.g., congestive heart failure programs). It represents a large, well-funded AAV platform incumbent with overlapping modality.

TypeEmerging player
Description

Sardocor is an emerging cardiac gene therapy developer focused on AAV-based treatments for inherited and acquired heart diseases. It competes in the same cardiac AAV niche as AaviGen but at an earlier stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aavigen Gmbh

Cardiovascular Gene Therapy / Biotechnologyaavigen.com

AaviGen GmbH is a Heidelberg-based preclinical-stage biotech developing heart-targeted AAV gene therapies for cardiovascular disease, using its proprietary next-CAP capsid engineering platform and lead product AVG-101 to address heart failure with organ-specific, low-dose cardiac gene delivery.

What Aavigen Gmbh does

AaviGen GmbH is a preclinical-stage biotechnology company founded in 2019 and headquartered in Heidelberg, Germany, that develops heart-targeted adeno-associated virus (AAV)-based gene therapies for cardiovascular and cardiopulmonary diseases. The company operates the proprietary next-CAP platform, which combines experimental and bioinformatic methodologies to molecularly engineer AAV capsids with organ-specific tropism, iteratively selecting for manufacturability, transduction, and transgene expression in human-relevant model systems. The resulting portfolio of heart-specific vectors is designed to enable precise, low-dose cardiac gene therapy via peripheral intravenous infusion, addressing the central challenge of off-target delivery and dose-dependent toxicity that constrains conventional AAV approaches.

The company's therapeutic pipeline is organized around five molecular target modules in heart failure: plasma membrane calcium channels, sarcoplasmic reticulum calcium release, mitochondrial energy metabolism, the contractile apparatus (cardiac titin), and beta-adrenergic signaling. Its lead candidate, AVG-101, uses the heart-specific AAV technology to target underlying molecular causes of cardiac muscle dysfunction. Manufacturing is outsourced to CDMO partner SK pharmteco under a multi-year preferred-partner agreement, and a 2026 research collaboration with Circio Holding ASA combines Circio's circVec circular RNA platform with AaviGen's capsids to pursue next-generation low-dose cardiac gene therapy.

AaviGen's business model is consistent with an early-stage biotech: revenue is expected to derive from out-licensing, co-development partnerships, and milestone payments once products advance, with no commercial products or disclosed pricing in market. The company is private, employs 1-10 people, has not publicly disclosed any institutional funding rounds, and is led by a founding team (Prof. Patrick Most, CEO; Dr. Martin Busch, COO; Prof. Marc Lerchenmüller, CFO; Prof. Hugo Katus, CMO) whose prior work includes the Troponin T test and the founding of InoCard (subsequently acquired by uniQure N.V.). It addresses an unmet need of 64.3 million heart failure patients globally with 67-75% five-year mortality, targeting pharmaceutical partners, CDMOs, and academic medical centers through executive-led business development rather than a commercial sales motion.

Aavigen Gmbh firmographics

Firmographics
Name
Aavigen Gmbh
Legal name
AaviGen GmbH
Website
https://aavigen.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
AaviGen GmbH is a Heidelberg-based preclinical-stage biotech developing heart-targeted AAV gene therapies for cardiovascular disease, using its proprietary next-CAP capsid engineering platform and lead product AVG-101 to address heart failure with organ-specific, low-dose cardiac gene delivery.
Ownership category
akta.pro rank

Aavigen Gmbh industry classification

Industry
Product category
Cardiovascular Gene Therapy / Biotechnology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cardiac gene therapy
  • AAV vector engineering
  • Cardiovascular biotechnology
  • Heart failure therapeutics
  • Viral vector platform

Where Aavigen Gmbh is headquartered

Location

Headquarters

HQ city
Heidelberg
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Aavigen Gmbh business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Gene Therapy Development and Commercialization: As a preclinical-stage biotech company, AaviGen is in the early phases of developing its gene therapy pipeline for heart failure and cardiovascular diseases. Revenue will derive from licensing deals, co-development partnerships, and eventual product commercialization once therapies receive regulatory approval.
  2. Strategic Partnerships and Manufacturing Agreements: Revenue may be generated through milestone payments and development fees from strategic partnerships such as the SK pharmteco manufacturing agreement and the Circio research collaboration.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Aavigen Gmbh product offering

Product offering

Core offering

AaviGen GmbH is a preclinical-stage biotechnology company that develops heart-targeted adeno-associated viral (AAV) vector-based gene therapies for cardiovascular and cardiopulmonary diseases. Its proprietary next-CAP platform engineers heart-specific AAV capsids used to build a cardiac gene therapy pipeline led by AVG-101 for heart failure, addressing five molecular target modules including calcium signaling, mitochondrial energetics, and contractile apparatus function.

Product overview

AaviGen is a preclinical-stage biotechnology company developing a portfolio of gene therapies for cardiovascular diseases. The company operates its next-CAP Platform to engineer proprietary heart-specific Adeno-Associated Viral (AAV) vectors, which form the foundation of its cardiac gene therapy pipeline. The lead product candidate is AVG-101 for heart failure treatment. The pipeline addresses five therapeutic target areas: plasma membrane calcium channels, sarcoplasmic reticulum calcium cycling, mitochondrial energy metabolism, contractile apparatus (cardiac titin), and beta-adrenergic signaling. The company leverages partnerships for manufacturing (SK pharmteco) and research collaborations (Circio) to advance its vector technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • next-CAP Platform Proprietary hybrid platform that integrates cutting-edge experimental and bioinformatic technologies to molecularly engineer AAV capsids, creating vector libraries with high quantitative and qualitative diversity for organ-specific gene therapy delivery. Intrinsically selects for manufacturability, transduction, and transgene expression through iterative systemic selection in human-relevant model systems.
  • AVG-101 Lead gene therapy product for the treatment of heart failure, leveraging AaviGen's proprietary heart-specific AAV vector technology to target and reverse underlying molecular causes of heart muscle dysfunction, administered via peripheral intravenous infusion.
  • Heart-Specific AAV Vectors Proprietary organ-specific adeno-associated viral vectors engineered for precise cardiac tropism, enabling targeted delivery of therapeutic genes to cardiomyocytes with unprecedented safety profiles by minimizing off-target organ delivery.
  • Cardiac Gene Therapy Pipeline (Five Therapeutic Modules) Therapeutic target pipeline addressing five key cardiac molecular areas: (1) plasma membrane voltage-dependent calcium channels, (2) sarcoplasmic reticulum ryanodine receptor calcium release, (3) mitochondria and energy metabolism via F1/0-ATPase, (4) contractile apparatus including cardiac titin and myofilament calcium sensitivity, and (5) beta-adrenergic signaling for desensitized downstream signaling.

Companies that use Aavigen Gmbh

Customer profile

Segments1 record

Ideal customer profiles3 records

Aavigen Gmbh technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aavigen Gmbh partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Circio Holding ASAcoreStrategic or Co-development Partner · 27 May 2026Circio and AaviGen announced a three-stage research collaboration to develop next-generation AAV gene therapy vectors specifically engineered for targeted, low-dose heart gene therapy. The partnership combines Circio's circVec circular RNA platform (demonstrating 40-fold enhanced gene expression in heart tissue) with AaviGen's proprietary heart-targeted AAV capsids. Stages include: (1) production of novel AAVs combining both technologies, (2) in vitro testing and characterization, and (3) in vivo validation focusing on biodistribution and gene expression profiles.
  • Will AdamsminorOthers · 4 June 2025Will Adams served as Lead Mentor for AaviGen during the German Accelerator U.S. Market Access Life Sciences Program and subsequently joined the AaviGen Advisory Board. He brings U.S. market expertise and industry connections as the company expands globally.
  • Prof. Dr. Toni CathomenminorOthers · 9 October 2024Prof. Dr. Toni Cathomen joined AaviGen's Scientific Advisory Board as an expert in targeted gene editing. He is Professor of Cell and Gene Therapy and Director of the Institute for Transfusion Medicine and Gene Therapy at the University Medical Center, University of Freiburg. His expertise in designer nucleases (CRISPR-Cas) and gene therapy applications complements AaviGen's AAV vector platform.
  • SK pharmtecocoreStrategic or Co-development Partner · 2 October 2024SK pharmteco, a global contract development and manufacturing organization (CDMO) for small molecules and advanced therapies, entered a multi-year manufacturing agreement as the preferred manufacturing partner for AaviGen's lead gene therapy product AVG-101 for heart failure. SK pharmteco provides process development and manufacturing of adeno-associated viral-based gene therapies, with recent investments in expanding manufacturing capacity to support development through commercialization.
  • University of HeidelbergminorOthersMultiple founding team members (Prof. Patrick Most heads the Molecular and Translational Cardiology Division; Prof. Hugo Katus is Director of Cardiology) maintain academic affiliations with the University of Heidelberg. The company was founded on research and translational expertise developed within this academic institution.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Aavigen Gmbh competitors and assessment

Company assessment

Broad incumbents

  • uniQure N.V. uniQure is an established gene therapy company where AaviGen's CEO previously led cardiac gene therapy development after acquiring InoCard. It is a relevant incumbent comparable given overlapping AAV platform and cardiovascular franchise, but operates at a much larger scale across multiple indications.
  • REGENXBIO: REGENXBIO is a leading AAV gene delivery platform company with NAV technology used across many partners including cardiac programs. It is comparable as a platform-level AAV peer even though its primary commercial focus is ophthalmology and rare disease.
  • Renovacor (acquired by Rocket Pharmaceuticals): Renovacor developed AAV-based gene therapies for cardiomyopathy associated with BAG3 mutations and was acquired by Rocket Pharmaceuticals. Rocket itself is a broader gene therapy company with cardiac-relevant programs, making it a relevant comparable for the cardiac AAV niche AaviGen targets.
  • Asklepios BioPharmaceutical (AskBio): AskBio, a Bayer subsidiary, develops AAV-based gene therapies across multiple therapeutic areas including cardiac indications (e.g., congestive heart failure programs). It represents a large, well-funded AAV platform incumbent with overlapping modality.

Direct peers

  • Lexeo Therapeutics: Lexeo is a clinical-stage gene therapy company focused on cardiovascular diseases, including AAV-based therapies for cardiomyopathies and heart failure. It is the most direct competitor to AaviGen given overlapping cardiac indication focus and AAV delivery approach.
  • Tenaya Therapeutics: Tenaya is developing genetic medicines for heart disease, including AAV-based gene therapies for cardiomyopathies and heart failure. Its pipeline targeting cardiac genetic and acquired disease states directly overlaps with AaviGen's therapeutic focus.
  • DiNAQOR: DiNAQOR is a preclinical-to-clinical-stage platform company developing AAV gene therapies specifically for cardiac diseases. It is highly comparable to AaviGen given the shared heart-targeted AAV modality and pipeline ambition.

Emerging players

  • Solid Biosciences: Solid Biosciences develops AAV gene therapies for cardiac and neuromuscular diseases, including programs for Duchenne muscular dystrophy with cardiac involvement. It overlaps with AaviGen on AAV modality and cardiac targeting, though it is at a later clinical stage.
  • Kriya Therapeutics: Kriya is a gene therapy company developing AAV-based therapies across multiple therapeutic areas with a platform-engineering approach. It is a comparable AAV platform peer, though its current disclosed pipeline does not focus primarily on cardiac indications.
  • Sardocor: Sardocor is an emerging cardiac gene therapy developer focused on AAV-based treatments for inherited and acquired heart diseases. It competes in the same cardiac AAV niche as AaviGen but at an earlier stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Aavigen Gmbh social profiles

Digital presence

Aavigen Gmbh financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aavigen Gmbh leadership team

Management profile

Number of profiles

Profiles4 records

Aavigen Gmbh funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aavigen Gmbh M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aavigen Gmbh

What does Aavigen Gmbh do?

AaviGen GmbH is a preclinical-stage biotechnology company that develops heart-targeted adeno-associated viral (AAV) vector-based gene therapies for cardiovascular and cardiopulmonary diseases. Its proprietary next-CAP platform engineers heart-specific AAV capsids used to build a cardiac gene therapy pipeline led by AVG-101 for heart failure, addressing five molecular target modules including calcium signaling, mitochondrial energetics, and contractile apparatus function.

Is Aavigen Gmbh a public or private company?

Aavigen Gmbh is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Aavigen Gmbh founded?

Aavigen Gmbh was founded in 2019. It employs 11 to 50 people.

Where is Aavigen Gmbh based?

Aavigen Gmbh is headquartered in Heidelberg, Germany, in the Europe region.

How does Aavigen Gmbh make money?

Two revenue lines are on record. Gene Therapy Development and Commercialization is the primary driver. The others are strategic Partnerships and Manufacturing Agreements.

Who are Aavigen Gmbh's main competitors?

Broad incumbents on record are uniQure N.V., REGENXBIO, Renovacor (acquired by Rocket Pharmaceuticals) and Asklepios BioPharmaceutical (AskBio). Direct peers are Lexeo Therapeutics, Tenaya Therapeutics and DiNAQOR. Emerging players are Solid Biosciences, Kriya Therapeutics and Sardocor.

Does Aavigen Gmbh have an API?

No public API is recorded for Aavigen Gmbh.

What industry is Aavigen Gmbh in?

Aavigen Gmbh's product category is Cardiovascular Gene Therapy / Biotechnology. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies. Its NAICS code is 541714 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales